Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

PAKISTAN: Risky Shots


Unnecessary injections, unsafe injection practices, and non-sterile syringes and needles are major factors contributing to the spread of hepatitis C virus (HCV) in Pakistan, according to Dr. Quaid Saeed, World Health Organization (WHO) national program officer on HIV and hepatitis. Other factors that contribute to the spread of the virus include poverty and illiteracy, roadside dentists’ use of unsterilized equipment, and “contaminated blood transfusions,” according to Saeed. Pakistan has had a Safe Blood Transfusion Act since 2002, but Saeed stated that only Punjab province has implemented the legislation fully. He estimated that Pakistan does not screen 40 percent of blood transfusions for HCV and HIV. Pakistan’s laws do not regulate syringe use.

Although current data estimated that 2–3 percent of Pakistanis are hepatitis B carriers and 4–5 percent of Pakistanis carry HCV, Saeed believed the numbers would be higher if officials surveyed the whole population. Although some people infected with HCV recover, up to 80 percent may become chronic carriers, according to Saeed. In contrast, approximately 80 percent of hepatitis B-infected patients recover from the virus. WHO defines national hepatitis prevalence between 2–8 percent as an “intermediate” risk. Saeed noted that Pakistan has the highest prevalence of chronic liver disease in the world.

Dr. Aftab Mohsin, a leading Pakistani liver and gastroenterology physician, confirmed that dentists, medical practitioners, and “quacks” are responsible for syringe reuse and misuse. In addition, Dr. Arshad Altaf, Pakistani volunteer for WHO’s Safety Injection Global Network, estimated that 90 percent of injections in Pakistan are unnecessary.

Mohsin stated that HCV treatment in Pakistan is “far worse” than syringe practice. Although HCV genotype 3 is the most prevalent form of HCV among Pakistani patients, most receive conventional interferon treatment instead of the preferred treatment of pegylated interferon.


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in May 15, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.